TaiMed Biologics
Zhubei City, Hsinchu County, Taiwan
Program data pending ClinicalTrials.gov matching
57.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (8)
○ EMA GMP
○ MHRA GMP
Quick Facts: TaiMed Biologics
- Signal Score
- 57.5/100
- Quality Compliance
- Assessment pending
- Headquarters
- Zhubei City, Hsinchu County, Taiwan
- Modalities
- Monoclonal Antibody, Biologics Drug Substance, Biologics Drug Product
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About TaiMed Biologics
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Biologics Drug Substance, Biologics Drug Product
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
55.0
Manufacturing site information being gathered
Modalities: Monoclonal Antibody, Biologics Drug Substance, Biologics Drug Product
Capacity assessment: 55.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press8 articles
Manufacturing site information being gathered
Modalities: Monoclonal Antibody, Biologics Drug Substance, Biologics Drug Product
Capacity assessment: 55.0/100
Recent News 8 articles
Taiwanese company wins FDA approval for HIV treatment with new mechanism of action - Fierce Pharma
TaiMed’s TMB-365/380 HIV Study Completes Phase 2b Enrollment Early - The Clinical Trial Vanguard
BIO 2024 Showcases the Emergence of Taiwan’s Biotech CDMO Market - geneonline.com
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study - GlobeNewswire
WuXi Biologics is producing a newly approved HIV med in the first Chinese biologics plant approved by the FDA - Fierce Pharma
WEP Clinical has partnered with TaiMed Biologics to launch a Trogarzo named patient program - European AIDS Treatment Group
TaiMed Biologics: Pioneering innovation in HIV therapy and CDMO services - The Japan Times
TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025 - PR Newswire
Frequently Asked Questions About TaiMed Biologics
What is TaiMed Biologics's CDMO Signal Score?
TaiMed Biologics has a Signal Score of 58/100, based on quality, operations, financial stability, and capacity data.
Evaluating TaiMed Biologics for a manufacturing program?
Use the free AI matchmaker to compare TaiMed Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Bora Pharmaceuticals
Taipei, Taiwan
Small Molecule (Oral Solid Dose), Biologics (Drug Substance & Drug Product), Monoclonal Antibody, Sterile Injectables / Aseptic Fill-Finish, Semi-Solids (creams, ointments, gels), Liquids (solutions, suspensions, ophthalmics, nasal sprays), Lyophilization
EirGenix
Zhubei City, Hsinchu County, Taiwan
Monoclonal Antibody, Bispecific/Polyclonal Antibody, Recombinant Protein, ADC, Biosimilars, Plasmid DNA
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 83.5
Monoclonal Antibody, Recombinant Protein, AAV, Plasmid DNA
Rentschler Biopharma
Laupheim, Germany
Signal Score: 79.9
Monoclonal Antibody, Recombinant Protein
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
Signal Score: 76.5
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish